Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2016-03-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
东莞证券股份有限公司关于公司发行股份及支付现金购买资产并募集配套资金暨关联交易之补充独立财务顾问报告（二）
Audit Report / Information Classification · 95% confidence The document is titled as a "Supplementary Independent Financial Advisor Report (II)" related to a transaction involving issuance of shares and cash payment for asset acquisition and fundraising, including related party transactions. It is issued by Dongguan Securities Co., Ltd. and addresses detailed due diligence, legal and financial opinions, and compliance with regulatory feedback from the China Securities Regulatory Commission (CSRC). The content includes detailed analysis of shareholding structures, legal compliance of share transfers, and financial data verification related to the transaction. This type of document is a specialized financial advisory report prepared for a major corporate transaction, not a general annual or quarterly report, earnings release, or a simple announcement. It is not a proxy statement, voting result, or management change notice. It is a standalone advisory report focusing on the transaction and related financial and legal due diligence. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. The document is substantive and detailed, not a brief announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Confidence is high given the detailed nature and purpose of the document. 9M 2015
2016-03-28 Chinese
关于签订发行股份及支付现金方式购买资产的业绩承诺补偿协议之补充协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a supplemental agreement related to a performance commitment compensation agreement for an asset purchase involving share issuance and cash payment. It details the parties involved, their shareholdings, and the terms of compensation obligations. The document is a formal announcement of a transaction-related agreement modification rather than a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on the terms of a capital transaction and related agreements. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2016-03-28 Chinese
第三届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the third meeting of the third board of directors of 福安药业（集团）股份有限公司, dated March 28, 2016. It details the approval of a supplemental agreement related to a previous asset purchase agreement involving issuance of shares and cash payment. The document includes voting results and confirms compliance with company law and procedures. There is no detailed financial data or comprehensive report content; rather, it is a board meeting resolution announcement. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2016-03-28 Chinese
关于收到《中国证监会行政许可项目审查二次反馈意见通知书》的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding receipt of a regulatory feedback notice from the China Securities Regulatory Commission (CSRC) related to the company's application for administrative approval of a share issuance to purchase assets. It includes details about the regulatory review process, requests for additional disclosures, and the company's commitment to respond within a specified timeframe. The document does not contain financial statements or detailed financial data but is a regulatory announcement about the status and feedback of a capital raising and asset purchase approval process. It is not a full report, earnings release, or management discussion but a regulatory filing announcing receipt of a regulatory feedback notice and the company's planned response. Therefore, it fits best under Regulatory Filings (RNS).
2016-03-25 Chinese
关于子公司收到药品补充申请批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about its subsidiary receiving drug approval certificates from a regulatory authority. It contains no financial data, no management discussion, no voting results, no meeting materials, and no detailed financial or operational report. The document is an official announcement of a regulatory approval event related to product registration, not a financial or governance report. The length is only 827 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-03-16 Chinese
关于子公司收到高新技术企业证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (680 characters) regarding a subsidiary receiving a High-Tech Enterprise Certificate, which grants tax benefits. It contains no financial statements or detailed financial data, nor does it present a report or results. It is an official company announcement about a regulatory or tax status update. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a certification or officer attestation. Given the content and length, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2016-03-11 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.